High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

Hiroyuki Daida, Tadateru Takayama, Takafumi Hiro, Masakazu Yamagishi, Atsushi Hirayama, Satoshi Saito, Tetsu Yamaguchi, Masunori Matsuzaki, COSMOS Investigators, Hiroyuki Daida, Tadateru Takayama, Takafumi Hiro, Masakazu Yamagishi, Atsushi Hirayama, Satoshi Saito, Tetsu Yamaguchi, Masunori Matsuzaki, COSMOS Investigators

Abstract

Background: The incidence of cardiac events is higher in patients with diabetes than in people without diabetes. The Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS) demonstrated significant plaque regression in Japanese patients with chronic coronary disease after 76 weeks of rosuvastatin (2.5 mg once daily, up-titrated to a maximum of 20 mg/day to achieve LDL cholesterol <80 mg/dl).

Methods: In this subanalysis of COSMOS, we examined the association between HbA1c and plaque regression in 40 patients with HbA1c ≥6.5% (high group) and 86 patients with HbA1c <6.5% (low group).

Results: In multivariate analyses, HbA1c and plaque volume at baseline were major determinants of plaque regression. LDL cholesterol decreased by 37% and 39% in the high and low groups, respectively, while HDL cholesterol increased by 16% and 22%, respectively. The reduction in plaque volume was significantly (p = 0.04) greater in the low group (from 71.0 ± 39.9 to 64.7 ± 34.7 mm(3)) than in the high group (from 74.3 ± 34.2 to 71.4 ± 32.3 mm(3)). Vessel volume increased in the high group but not in the low group (change from baseline: +4.2% vs -0.8%, p = 0.02). Change in plaque volume was significantly correlated with baseline HbA1c.

Conclusions: Despite similar improvements in lipid levels, plaque regression was less pronounced in patients with high HbA1c levels compared with those with low levels. Tight glucose control during statin therapy may enhance plaque regression in patients with stable coronary disease.

Trial registration: ClinicalTrials.gov, Identifier NCT00329160.

Figures

Figure 1
Figure 1
Associations between HbA1c and plaque volume change. Associations in all patients (a), in patients with diabetes mellitus (b), and in non-diabetic patients (c).

References

    1. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T. et al.Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) J Am Coll Cardiol. 2009;54(4):293–302. doi: 10.1016/j.jacc.2009.04.033.
    1. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC. et al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565. doi: 10.1001/jama.295.13.jpc60002.
    1. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B. et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. doi: 10.1001/jama.291.9.1071.
    1. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061–1068. doi: 10.1161/01.CIR.0000140261.58966.A4.
    1. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS) Circ J. 2009;73(11):2110–2117. doi: 10.1253/circj.CJ-09-0358.
    1. Takayama T, Hiro T, Yamagishi M, Daida H, Saito S, Yamaguchi T, Matsuzaki M. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects) Circ J. 2007;71(2):271–275. doi: 10.1253/circj.71.271.
    1. Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K. et al.Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J) Circ J. 2011;75(5):1071–1079. doi: 10.1253/circj.CJ-11-0141.
    1. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K. et al.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. doi: 10.1001/jama.299.13.1561.
    1. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2225. doi: 10.1001/jama.292.18.2217.
    1. Sipahi I, Tuzcu EM, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B, Balog C, Shishehbor M, Magyar WA, Crowe TD. et al.Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med. 2007;147(1):10–18.
    1. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T. et al.Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome–serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial) Circ J. 2010;74(6):1165–1174. doi: 10.1253/circj.CJ-09-0766.
    1. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P. et al.Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55(24):2736–2742. doi: 10.1016/j.jacc.2010.01.050.
    1. Bonora E, Kiechl S, Mayr A, Zoppini G, Targher G, Bonadonna RC, Willeit J. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care. 2011;34(4):1038–1040. doi: 10.2337/dc10-1180.
    1. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, Eliasson B. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) J Intern Med. 2010;268(5):471–482. doi: 10.1111/j.1365-2796.2010.02265.x.
    1. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25(11):1295–1301.
    1. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM. et al.American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(5):1478–1492. doi: 10.1016/S0735-1097(01)01175-5.
    1. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes M et al.Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation. 2010;1(5):212–228.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):S62–69.
    1. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255–262. doi: 10.1016/j.jacc.2008.03.051.
    1. Berry C, Noble S, Gregoire JC, Ibrahim R, Levesquie S, Lavoie MA, L'Allier PL, Tardif JC. Glycaemic status influences the nature and severity of coronary artery disease. Diabetologia. 2010;53(4):652–658. doi: 10.1007/s00125-009-1651-x.
    1. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des. 2008;14(10):979–986. doi: 10.2174/138161208784139684.
    1. Walcher D, Marx N. Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol. 2009;31(1):103–111. doi: 10.1007/s00281-009-0144-9.
    1. Nasu K, Tsuchikane E, Katoh O, Fujita H, Surmely JF, Ehara M, Kinoshita Y, Tanaka N, Matsubara T, Asakura Y. et al.Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart. 2008;94(4):429–433.
    1. Sano K, Kawasaki M, Okubo M, Yokoyama H, Ito Y, Murata I, Kawai T, Tsuchiya K, Nishigaki K, Takemura G. et vivo quantitative tissue characterization of angiographically normal coronary lesions and the relation with risk factors: a study using integrated backscatter intravascular ultrasound. Circ J. 2005;69(5):543–549. doi: 10.1253/circj.69.543.
    1. Parathath S, Grauer L, Huang LS, Sanson M, Distel E, Goldberg IJ, Fisher EA. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes. 2011;60(6):1759–1769. doi: 10.2337/db10-0778.
    1. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772. doi: 10.1016/S0140-6736(09)60697-8.
    1. Jimenez-Quevedo P, Suzuki N, Corros C, Ferrer C, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, Banuelos C, Escaned J, Fernandez C. et al.Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. Diabetes. 2009;58(1):209–214. doi: 10.2337/db08-0376.
    1. Reddy HK, Koshy SK, Foerst J, Sturek M. Remodeling of coronary arteries in diabetic patients-an intravascular ultrasound study. Echocardiography. 2004;21(2):139–144. doi: 10.1111/j.0742-2822.2004.03014.x.
    1. Chhatriwalla AK, Nicholls SJ, Wang TH, Wolski K, Sipahi I, Crowe T, Schoenhagen P, Kapadia S, Tuzcu EM, Nissen SE. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. 2009;53(13):1110–1115. doi: 10.1016/j.jacc.2008.09.065.
    1. Koh KK, Quon MJ, Sakuma I, Han SH, Choi H. Lee K. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol, Shin EK; 2011.
    1. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009;63(9):1308–1313. doi: 10.1111/j.1742-1241.2009.02101.x.
    1. Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;11:1141–1148.
    1. Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J Clin Pract. 2011;65(6):679–683. doi: 10.1111/j.1742-1241.2011.02655.x.
    1. Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesauro M, Lauro D. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis. 2010;210(1):199–201. doi: 10.1016/j.atherosclerosis.2009.11.021.
    1. Lamendola C, Abbasi F, Chu JW, Hutchinson H, Cain V, Leary E, McLaughlin T, Stein E, Reaven G. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol. 2005;95(2):189–193. doi: 10.1016/j.amjcard.2004.09.005.
    1. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS. et al.Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011;10:103. doi: 10.1186/1475-2840-10-103.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel